Kennedy Capital Management LLC Decreases Stock Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Kennedy Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 21.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,468,519 shares of the biotechnology company's stock after selling 412,559 shares during the period. Kennedy Capital Management LLC owned about 2.47% of Aldeyra Therapeutics worth $7,328,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Catalyst Funds Management Pty Ltd boosted its holdings in Aldeyra Therapeutics by 2,083.3% during the fourth quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 12,500 shares during the last quarter. U.S. Capital Wealth Advisors LLC acquired a new stake in Aldeyra Therapeutics during the 4th quarter valued at $69,000. BNP Paribas Financial Markets boosted its holdings in shares of Aldeyra Therapeutics by 253.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 14,229 shares of the biotechnology company's stock worth $77,000 after buying an additional 10,201 shares during the period. Captrust Financial Advisors boosted its holdings in shares of Aldeyra Therapeutics by 89.3% during the third quarter. Captrust Financial Advisors now owns 19,261 shares of the biotechnology company's stock worth $104,000 after acquiring an additional 9,087 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company's stock valued at $112,000 after acquiring an additional 2,822 shares during the period. 59.71% of the stock is owned by institutional investors.

Remove Ads

Aldeyra Therapeutics Price Performance

NASDAQ ALDX traded up $0.21 on Monday, reaching $2.12. The company had a trading volume of 2,105,216 shares, compared to its average volume of 686,322. Aldeyra Therapeutics, Inc has a fifty-two week low of $1.14 and a fifty-two week high of $7.20. The business has a 50 day moving average of $5.54 and a two-hundred day moving average of $5.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.30). On average, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current year.

Insider Buying and Selling at Aldeyra Therapeutics

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now owns 5,875,851 shares in the company, valued at approximately $8,343,708.42. This represents a 36.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.50% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have commented on ALDX shares. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aldeyra Therapeutics in a research note on Friday, April 4th. BTIG Research dropped their price objective on shares of Aldeyra Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a research note on Monday, April 7th.

Aldeyra Therapeutics Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.